Version July 2025
Note: Concurrent use of rimegepant for both migraine treatment and prevention has not been evaluated (Ref).
Migraine, moderate to severe, acute treatment (alternative agent):
Note: Consider use if triptans are contraindicated (eg, cardiovascular risk factors), ineffective, or poorly tolerated. Administration early in the course of a migraine attack, at the first sign of pain, may improve response to treatment (Ref).
Oral: 75 mg as a single dose. Maximum: 75 mg per 24 hours (Ref).
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
CrCl ≥15 mL/minute: No dosage adjustment necessary.
CrCl <15 mL/minute: Avoid use (has not been studied).
Patients on dialysis: Avoid use (has not been studied).
Mild to moderate impairment (Child-Pugh class A, B): No dosage adjustment necessary.
Severe impairment (Child-Pugh class C): Avoid use.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Gastrointestinal: Abdominal pain (≤2%), dyspepsia (≤2%), nausea (2% to 3%)
<1%: Hypersensitivity: Hypersensitivity reaction (including type IV hypersensitivity reaction)
Postmarketing: Cardiovascular: Hypertension (including exacerbation of hypertension), Raynaud disease (including exacerbation of Raynaud disease)
Hypersensitivity (including delayed serious hypersensitivity) to rimegepant or any component of the formulation.
Concerns related to adverse effects:
• Hypersensitivity: Hypersensitivity reactions, including dyspnea, rash, and delayed serious reactions, have been reported; discontinue therapy if hypersensitivity occurs.
• Hypertension: New-onset and worsening of preexisting hypertension, including cases requiring pharmacological treatment or hospitalization, have been reported with calcitonin gene-related peptide (CGRP) antagonists. Onset most frequently occurred within 7 days of administration but may occur at any time. Consider discontinuing treatment in patients whom an alternative etiology is not established.
• Raynaud phenomenon: New-onset and recurrence/worsening of preexisting Raynaud phenomenon, including cases requiring hospitalization and causing debilitating pain, have been reported with CGRP antagonists. Onset occurred at a median of 1.5 days after administration; most cases resolved after discontinuation of therapy. Consider discontinuing treatment if signs and symptoms of Raynaud phenomenon occur; consider evaluation by a health care provider if symptoms do not resolve upon discontinuation of therapy.
Disease-related concerns:
• Cardiovascular disease: May cause hypertension; use with caution in patients with hypertension or risk factors for hypertension.
• Hepatic impairment: Use is not recommended in patients with severe hepatic impairment.
• Raynaud phenomenon: May cause new or worsening Raynaud phenomenon; use with caution in patients with a history of Raynaud phenomenon.
• Renal impairment: Use is not recommended in patients with end-stage renal disease.
Other warnings and precautions:
• Appropriate use: The safety of using more than 18 doses in a 30-day period has not been established.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet Disintegrating, Oral, as sulfate:
Nurtec: 75 mg [contains menthol]
No
Tablet, orally-disintegrating (Nurtec Oral)
75 mg (per each): $154.35
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet Disintegrating, Oral, as sulfate:
Nurtec: 75 mg [contains menthol]
Oral: Using dry hands, peel foil covering blister to remove tablet; do not push tablet through the foil. Immediately place tablet on or under tongue. The tablet will disintegrate in saliva (can be swallowed without additional liquid).
Migraine, prevention: Preventative treatment of migraine in adults (Croop 2021; manufacturer's labeling).
Migraine, moderate to severe, acute treatment: Acute treatment of migraine with or without aura in adults.
Rimegepant may be confused with rimonabant [multiple international markets].
Nurtec may be confused with Noctec brand name for chloral hydrate [United States, Australia, Canada, United Kingdom]; Nutren brand name for enteral nutrition preparation [multiple international markets]; Nutrex brand name for nutritional supplement [India, Italy].
Substrate of BCRP, CYP2C9 (Minor), CYP3A4 (Major), P-glycoprotein (Minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Asciminib: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor
CYP3A4 Inducers (Moderate): May decrease serum concentration of Rimegepant. Risk X: Avoid
CYP3A4 Inducers (Strong): May decrease serum concentration of Rimegepant. Risk X: Avoid
CYP3A4 Inhibitors (Moderate): May increase serum concentration of Rimegepant. Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine. Risk D: Consider Therapy Modification
CYP3A4 Inhibitors (Strong): May increase serum concentration of Rimegepant. Risk X: Avoid
Elacestrant: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Erdafitinib: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates. Risk D: Consider Therapy Modification
Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification
Futibatinib: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Gilteritinib: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Grapefruit Juice: May increase serum concentration of Rimegepant. Management: Consider avoiding grapefruit if taking rimegepant for the acute treatment of migraine. Avoid a second dose of rimegepant within 48 hours in regular grapefruit juice consumers. No action is needed if using rimegepant for prevention of episodic migraine. Risk D: Consider Therapy Modification
Lasmiditan: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid
Levacetylleucine: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
P-glycoprotein/ABCB1 Inhibitors: May increase serum concentration of Rimegepant. Management: Avoid administration of another dose of rimegepant within 48 hours if given concomitantly with a P-glycoprotein (P-gp) inhibitor. Risk D: Consider Therapy Modification
Pretomanid: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Primaquine: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
Sparsentan: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid
Taurursodiol: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk X: Avoid
Venetoclax: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Avoid concomitant use of venetoclax and oral p-glycoprotein (P-gp) substrates if possible. If combined use is unavoidable, administer the P-gp substrate at least 6 hours before venetoclax to minimize the potential for an interaction. Risk D: Consider Therapy Modification
Xanomeline: May increase serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Risk C: Monitor
In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).
Following oral administration of rimegepant to pregnant rats during the period of organogenesis, adverse fetal events were only observed at doses that also caused maternal toxicity; pre- and postnatal developmental studies in rats were inadequate. Adverse events were not observed following oral administration to pregnant rabbits during the period of organogenesis.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist. Based on animal data, CGRP may help regulate placental blood flow, uterine relaxation, and maintain BP; CGRP antagonists could potentially increase the risk of gestational hypertension and preeclampsia (Dodick 2019). The risk of hypertensive disorders, including preeclampsia and eclampsia, are also increased in pregnant patients with migraine (ACOG 2022; Dodick 2019).
In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). Oral CGRP receptor antagonists are not currently recommended for the prevention of migraine or treatment of acute migraine in pregnant patients due to lack of data (ACOG 2022).
Data collection to monitor pregnancy and infant outcomes following exposure to rimegepant is ongoing. Health care providers are encouraged to enroll patients exposed to rimegepant during pregnancy in the Nurtec Pregnancy Registry (877-366-0324 or nurtecpregnancyregistry.com).
Rimegepant is present in breast milk.
Data related to the presence of rimegepant in breast milk are available from 12 lactating patients 2 weeks to 6 months postpartum. Patients were administered a single dose of rimegepant 75 mg and breast milk was collected at specified intervals for 36 hours after the dose. The median time to peak concentrations of rimegepant in breast milk was 2 hours after the dose. The maximum concentrations of rimegepant in breast milk and maternal plasma were 169.6 ng/mL and 759.2 ng/mL, respectively. Using the mean milk concentration, authors of the study calculated the estimated exposure to the breastfeeding infant to be 0.005 mg/kg/day (relative infant dose [RID] 0.51% based on a mean maternal dose of 1.04 mg/kg/day). Infants were not breastfed during the study (Baker 2022). In general, breastfeeding is considered acceptable when the RID of a medication is <10% (Anderson 2016; Ito 2000).
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. In general, preventive treatment for migraine in lactating patients should be avoided. When needed, therapy should be individualized considering the available safety data and needs of the patient (AHS [Ailani 2021]). Oral calcitonin gene-related peptide receptor antagonists are not currently recommended for the prevention of migraine or treatment of acute migraine in lactating patients due to lack of data (ACOG 2022).
New-onset hypertension or worsening of preexisting hypertension; in patients with Raynaud phenomenon, worsening or recurrence of signs/symptoms.
Rimegepant is a calcitonin gene-related peptide receptor antagonist.
Onset:
Migraine treatment: ≤2 hours (Croop 2019).
Migraine prevention: ≤4 weeks (Croop 2021).
Duration: Migraine treatment: Up to 48 hours (Croop 2019).
Absorption: Cmax decreased 42% to 53% and AUC decreased 32% to 38% following a high-fat meal. Cmax decreased 36% and AUC decreased 28% following a low-fat meal.
Distribution: Vdss: 120 L.
Protein binding: ~96%.
Metabolism: Primarily hepatic via CYP3A4 and to a lesser extent by CYP2C9.
Bioavailability: ~64%.
Half-life elimination: ~11 hours.
Time to peak: 1.5 hours; delayed 1 hour following a high-fat meal.
Excretion: Urine (51% as unchanged drug); feces (42% as unchanged drug).
Hepatic function: Cmax and AUC increased ~2-fold in patients with severe hepatic impairment (Child-Pugh class C) following a single 75 mg dose compared to healthy controls.
